Chronic plaque psoriasis

Active Ingredient: Efalizumab

Indication for Efalizumab

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA.

For this indication, competent medicine agencies globally authorize below treatments:

0.7 mg/kg once and thereafter 1 mg/kg weekly


Dosage regimens

Subcutaneous, 0.7 milligrams efalizumab per kilogram of body weight, one dose, over the duration of 1 week. Afterwards, subcutaneous, 1 milligrams efalizumab per kilogram of body weight, once weekly, over the duration of 11 weeks.

Detailed description

An initial single dose of 0.7 mg/kg body weight is given followed by weekly injections of 1.0 mg/kg body weight (maximum single dose should not exceed a total of 200 mg). The volume to be injected should be calculated as follows:

DoseVolume to be injected per 10 kg body weight
Single initial dose: 0.7 mg/kg0.07 ml
Subsequent doses: 1 mg/kg0.1 ml

The duration of therapy is 12 weeks. Therapy may be continued only in patients who responded to treatment (PGA good or better).

Dosage considerations

Injection sites should be rotated.

Active ingredient


Efalizumab is a recombinant humanized monoclonal antibody that binds specifically to the CD11a subunit of LFA-1 (lymphocyte function-associated antigen-1), a leukocyte cell surface protein. By this mechanism, efalizumab inhibits the binding of LFA-1 to ICAM-1, which interferes with T lymphocytes adhesion to other cell types. By preventing LFA-1/ICAM binding, efalizumab may alleviate signs and symptoms of psoriasis by inhibiting several stages in the immunologic cascade.

Read more about Efalizumab

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.